The type-based Chimeric Antigen Receptor T Cell Therapy segmentation distinguishes products by the biological source of the T cells, a variable that directly conditions manufacturing complexity, regulatory pathway and cost structure. Autologous therapies—those engineered from the patient’s own lymphocytes—dominate current market value because they were first-to-approval and carry a lower immunogenic risk, yet they impose vein-to-vein times averaging 3–4 weeks, limiting scalability. Allogeneic (off-the-shelf) formats, while still nascent, are attracting >45% of sector-specific venture funding as they promise scalable, lower-cost inventory and on-demand dosing; early trial data indicate 30–40% reductions in hospital resource use, suggesting potential to enlarge the addressable market by serving patients unsuitable for leukapheresis. Within allogeneic, CRISPR-edited healthy-donor T cells and cord-blood-derived variants represent discrete technology platforms, each with distinct graft-versus-host and persistence profiles. As regulatory agencies issue draft guidance for genome-edited products, the allogeneic sub-segment is projected to move from <5% of commercial share in 2023 to ~18% by 2030, re-drawing the therapy’s market taxonomy.
